National Association of Epilepsy Centers

EnlitenAI Emerges as a Prominent Contender at the Digital Health Awards

Retrieved on: 
Friday, September 22, 2023
Seizure, Heart, University, Face, National Association of Epilepsy Centers, Baylor College of Medicine, Baylor University, DRS, CO, UCSF, UCHealth, Fort Collins, Colorado, Growth, Hospital, Medical device, Pharmaceutical industry, Neurology

Fort Collins,CO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- EnlitenAI , an Innosphere Ventures graduate company, proudly announces its selection as a quarterfinalist in the prestigious Digital Health Awards presented by the Digital Health Hub Foundation.

Key Points: 
  • Fort Collins,CO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- EnlitenAI , an Innosphere Ventures graduate company, proudly announces its selection as a quarterfinalist in the prestigious Digital Health Awards presented by the Digital Health Hub Foundation.
  • Out of an overwhelming 1,500 submissions, EnlitenAI has secured its spot due to its innovative focus on using AI to personalize seizure management.
  • This team has been instrumental not only in charting EnlitenAI’s functionality roadmap but also in designing groundbreaking clinical investigations."
  • Mark Goldstein, Chairman of Digital Health Hub Foundation, praised the high caliber of entrants this year, stating, "We are so impressed by the pioneering work in digital health happening on a global scale.

Children’s Hospital Los Angeles Names Sucheta Joshi, MD, MS, FAAP, FAES as Incoming Medical Director of Comprehensive Epilepsy Program

Retrieved on: 
Thursday, June 29, 2023
Health, Hospitals, Epilepsy, Seth, Telehealth, Bachelor, University of Mumbai, University, MBBS, National Association of Epilepsy Centers, Bachelor of Medicine, Bachelor of Surgery, CHLA, Policy, Advisory Committee, Pediatrics (journal), King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Service, American Academy, Multimedia, AAP, Research, Neurology, Montreal Neurological Institute and Hospital, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Stanford University School of Medicine, University of Michigan School of Dentistry, Michigan Medicine, Pediatric Neurology, Public health, Committee, Medical director, Division, Children's Hospital Los Angeles, FAES, University of Michigan School of Public Health, National Association, Nursing, Pharmaceutical industry, Pediatrics, FAAP, MD, Medicine

View the full release here: https://www.businesswire.com/news/home/20230629162494/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230629162494/en/
    Sucheta Joshi, MD, MS, FAAP, FAES, has been named as incoming Medical Director of the Neurological Institute Comprehensive Epilepsy Program at Children’s Hospital Los Angeles (CHLA).
  • She most recently has served as Service Chief of Pediatric Neurology and Medical Director of Pediatric Epilepsy at Michigan Medicine, the academic medical center of the University of Michigan, where she launched a complex epilepsy clinical program and an inpatient pediatric epilepsy service.
  • In her new role, Dr. Joshi will lead and expand the Comprehensive Epilepsy Program at CHLA and will grow programs such as telehealth, precision health trials, adult transition, team-based clinics and surgical epilepsy.
  • Joshi’s leadership will help us reach the full potential of our Comprehensive Epilepsy Program.

Phoenix Children's to Unveil Redesigned Neurodiagnostic Sleep and EEG Laboratory

Retrieved on: 
Monday, April 24, 2023
Epilepsy, Seizure, Heart, American Academy of Sleep Medicine, National Association of Epilepsy Centers, Phoenix Children's Hospital, CPAP, Life, Noise, Bed, BNI, Parent, Sleep, Abrazo Arrowhead Campus, EMG, Registered, Narcolepsy, American Academy, Sleep apnea, Nerve injury, EMG, Inc., Headboard (furniture), Barrow Neurological Institute, American Board of Commissioners for Foreign Missions, MD, Patient, Sleep disorder, EEG, Coffee, Hospital, National Association, Ferhat Ozcep, Relaxation, Environment, Neurology, Caregiver, Pharmaceutical industry, Nursing, Residential care

PHOENIX, April 24, 2023 /PRNewswire/ -- A new and expanded neurodiagnostic laboratory will soon open at Phoenix Children's to improve comfort and care for children undergoing sleep studies, electroencephalogram (EEG) and electromyography (EMG) testing and nerve conduction studies. One of many expansion projects underway at Phoenix Children's Hospital – Thomas Campus, the neurodiagnostic laboratory is part of Barrow Neurological Institute at Phoenix Children's and boasts 6,900 square feet, including eight patient rooms, a family lounge and designated work areas for clinicians.

Key Points: 
  • PHOENIX, April 24, 2023 /PRNewswire/ -- A new and expanded neurodiagnostic laboratory will soon open at Phoenix Children's to improve comfort and care for children undergoing sleep studies, electroencephalogram (EEG) and electromyography (EMG) testing and nerve conduction studies.
  • The neurodiagnostic laboratory is led by Randa Jarrar, MD , pediatric epileptologist and medical director of clinical neurophysiology and Rupali Drewek, MD , pediatric pulmonologist and sleep medicine specialist and medical director of the Sleep Disorders Program at Phoenix Children's.
  • At night, the sleep laboratory will focus on overnight testing and diagnostics for children who may have sleep disorders , including sleep apnea, narcolepsy or pediatric limb movement disorder.
  • The Epilepsy Program is further accredited by the Laboratory Accreditation Board of the American Board of Registered EEG Technologists (ABRET) for its excellence in conducting and interpreting EEG tests.

Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Monday, April 24, 2023
Epilepsy, MPC, Therapy, AAN, NYU Langone Health, New York University Grossman School of Medicine, Convention, American Academy, New York University, Channel modulator, Department of Neurology, Xuanwu hospital, National Association of Epilepsy Centers, MD, National Primate Research Exhibition Hall, Patient, Physician, Annual general meeting, Seizure, Safety, OLE, American Academy of Neurology, Pharmaceutical industry, Drug, Xenon, Neurology, Medicine

VANCOUVER, British Columbia and BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its upcoming oral and poster presentations at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, MA.

Key Points: 
  • VANCOUVER, British Columbia and BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its upcoming oral and poster presentations at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, MA.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited to showcase our XEN1101 epilepsy program at the 2023 AAN meeting.
  • Importantly, patients with epilepsy are experiencing continued seizure reduction and extended periods of seizure freedom.
  • XEN1101 continues to be generally well-tolerated in the OLE with adverse events consistent with prior results and other anti-seizure medications.

Charlotte's Web forms Joint Venture with BAT and AJNA BioSciences to Seek FDA-Approval for Proprietary Full Spectrum Hemp Extract Botanical Drug

Retrieved on: 
Thursday, April 6, 2023
Charlotte's Web, Epilepsy, BAT, LSE, Indian stock exchange, CW, Nicotine, MI, Genetics, Lennox–Gastaut syndrome, NYU, DSM-IV codes, Cannabinoid, New York University Grossman School of Medicine, Effective interest rate, CWEB, Research, Tobacco, Joint venture, JV, US, Investigational New Drug, National Association of Epilepsy Centers, Natural American Spirit, Transaction, Psychiatry, Cannabis, Drug development, TSX, Commercial, FDA, Langone, American Tobacco Company, Mental health, IND, News, NYSE, BTI, Pharmaceutical industry, Security (finance), New York University, Neurology, Neurosurgery

This novel botanical drug will be developed from certain proprietary hemp genetics of CW.

Key Points: 
  • This novel botanical drug will be developed from certain proprietary hemp genetics of CW.
  • The JV plans to engage with the FDA to file an Investigational New Drug ("IND") application and commence Phase I clinical development in 2023.
  • The JV plans to use the initial US$10 million investment for the clinical development of a novel hemp botanical IND.
  • I believe the properties of cannabis and hemp are well suited for the FDA's new Botanical Drug Development pathway", Dr. Devinsky said.

Vial Announces New Central Nervous System Scientific Advisory Board Member, Dr. Jacqueline French of the Epilepsy Study Consortium and NYU Grossman School of Medicine.

Retrieved on: 
Friday, January 13, 2023
NYU Langone Health, SAB, EEG, Mount Sinai Hospital, CNS, International League Against Epilepsy, AAN, MD, Epilepsy, Drug discovery, National Association of Epilepsy Centers, Patient, Yale University, American Academy, American Academy of Neurology, Research, SAN, Brown University, NYU, Fine chemical, Pharmaceutical industry, Vial, Neurology

Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.

Key Points: 
  • Dr. French is a professor of neurology at the NYU Grossman School of Medicine, co-director of epilepsy clinical trials for NYU Langone Health's Comprehensive Epilepsy Center, and president, director, and founder of The Epilepsy Study Consortium.
  • After receiving her medical education at Brown University, she completed a residency in neurology at Mount Sinai Hospital in New York.
  • Thereafter, she pursued further training through a fellowship in EEG and epilepsy at Mount Sinai Hospital and Yale University.
  • We are pleased to welcome Dr. French as she is an esteemed leader in clinical neurology research," said Simon Burns, CEO and Co-founder of Vial.

EQS-News: PRECISIS GmbH: EASEE – ­­­World's first minimally invasive brain pacemaker for the treatment of epilepsy receives CE-certification and is available immediately

Retrieved on: 
Friday, September 23, 2022
Cortex, Adult, MDR, National Association of Epilepsy Centers, Safety, Movement, Seizure, Department, Medical device regulation, Brain, FDA, TDCS, MDD, Thalamus, University Medical Center Freiburg, Clinical study design, Electrode, Medical Devices Directive, The New England Journal of Medicine, Certification, Patient, Epilepsy, Environment, FCS, CE, Quality of life, CTO, Psychology, Neuro, Scalp, Food, Medical device, Disease, Trial of the century, Freedom, Medicine, DEPT, Pharmaceutical industry, Wood drying, MD

Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.

Key Points: 
  • Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.
  • These drug-refractory patients wait an average of 22 years before they are offered further technical or surgical treatment options.
  • With this new, risk-minimized EASEE method, the treatment spectrum is expanded in the early phases of the disease."
  • EASEE is an acronym for Epicranial Application of Stimulation Electrodes for Epilepsy.

Medical Marijuana, Inc. Subsidiary HempMeds® Collaborates With Leading Research Hospital in Argentina to Study the Efficiency of CBD for Adult Epilepsy

Retrieved on: 
Wednesday, July 6, 2022
Efficiency, FDA, OTC, Patient, Securities Act of 1933, Securities Exchange Act of 1934, Research, Neurodegeneration, CNBC, GLOBE, Company, Disease, Medical cannabis, Neuroscience, Medical Marijuana, Inc., World, SAN, Food, The O.C., Hospital, Drug Quality and Security Act, Digital reference, Organization, World Health Organization, PDR, CA, Complex system, Executive, National Association of Epilepsy Centers, Safety, Food and Drug Administration, Nature, Safe harbor, Ministry, Epilepsy, Drug, Medical device, CBD

The Ministry of Health of Argentina has authorized Hospital del Cruce, the leading research venue in Argentina, to import HempMeds products and execute the study.

Key Points: 
  • The Ministry of Health of Argentina has authorized Hospital del Cruce, the leading research venue in Argentina, to import HempMeds products and execute the study.
  • We have been involved in CBD research efforts in Latin America since 2017, collaborating with top medical doctors and organizations.
  • As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands such as Real Scientific Hemp Oil.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

MEGIN announces sale of TRIUX™ neo to University of Nebraska Medical Center

Retrieved on: 
Monday, March 14, 2022
UNMC, Faculty, Biomarker, Disease, Assistant professor, Alzheimer's disease, Nebraska Medicine, University, Patient, Department, Cognition, Research, University of Nebraska Medical Center, Neurology, Lewy body dementias, Frontotemporal dementia, Magnetoencephalography, Sleep, Seizure, Nature, Dementia, Multimedia, Brain mapping, Brain, National Association of Epilepsy Centers, MEG, Language, Sale, Technology, Union, Epilepsy, View, Medical imaging

HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).

Key Points: 
  • HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).
  • MEGIN's TRIUX neo is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with exquisite resolution.
  • The TRIUX neo offers the most precise functional information currently available on the market for functional brain imaging in children, adolescents and adults.
  • Copyright 2022 MEGIN TRIUX neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries.

MEGIN announces sale of TRIUX™ neo to University of Nebraska Medical Center

Retrieved on: 
Monday, March 14, 2022
UNMC, Faculty, Biomarker, Disease, Assistant professor, Alzheimer's disease, Nebraska Medicine, University, Patient, Department, Cognition, Research, University of Nebraska Medical Center, Neurology, Lewy body dementias, Frontotemporal dementia, Magnetoencephalography, Sleep, Seizure, Nature, Dementia, Brain mapping, Brain, National Association of Epilepsy Centers, MEG, Language, Sale, Technology, Union, Epilepsy, Medical imaging

HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).

Key Points: 
  • HELSINKI, March 14, 2022 /PRNewswire/ --MEGIN is delighted to announce the purchase of our fourth-generation magnetoencephalography (MEG) technology, the TRIUX neo, by the University of Nebraska Medical Center (UNMC).
  • MEGIN's TRIUX neo is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with exquisite resolution.
  • The TRIUX neo offers the most precise functional information currently available on the market for functional brain imaging in children, adolescents and adults.
  • Copyright 2022 MEGIN TRIUX neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries.